ARTICLE | Deals
Novartis to build out neuropsychiatry pipeline via Cadent takeout
December 17, 2020 7:28 PM UTC
Cadent’s neuropsychiatry portfolio gives Novartis clinical programs in an area that the pharma has been eyeing for business development opportunities.
Novartis AG (NYSE:NVS; SIX:NOVN) will acquire Cadent Therapeutics Inc. for $210 million up front and up to $560 million in milestones. ...